Clinical characteristics of all 3 SARS-CoV-2 cohorts
| . | Asymptomatic SARS-CoV-2 (n = 289) . | COVID-19 (n = 426) . | MIS-C/ MIS-C like (n = 138) . |
|---|---|---|---|
| Age, y | |||
| Median | 10 | 10 | 10 |
| IQR | 3-15 | 1-16 | 6-14 |
| Male sex | 144 (50) | 226 (53) | 75 (54) |
| Ethnicity | |||
| Hispanic | 125 (43) | 228 (54) | 57 (41) |
| Non-Hispanic | 139 (48) | 167 (39) | 69 (50) |
| Unknown/other | 25 (9) | 31 (7) | 12 (9) |
| Race | |||
| White | 151 (52) | 234 (55) | 77 (56) |
| African American | 74 (26) | 89 (21) | 39 (28) |
| Asian | 2 (1) | 6 (1) | 4 (3) |
| Other/unknown | 62 (21) | 97 (23) | 18 (13) |
| African American race and/or Hispanic ethnicity | 198 (69) | 315 (74) | 96 (70) |
| Length of stay, d | |||
| Median | 3 | 3 | 6 |
| IQR | 1-7 | 2-7 | 4-10 |
| Comorbidity | |||
| Respiratory | 22 (8) | 90 (21) | 16 (12) |
| Cardiac | 13 (5) | 38 (9) | 5 (4) |
| Cancer | 25 (9) | 39 (9) | 5 (4) |
| Obesity | 61 (21) | 114 (27) | 45 (33) |
| Diabetes | 17 (6) | 15 (4) | 0 |
| Immunodeficiency | 10 (3) | 18 (4) | 1 (1) |
| Sickle cell disease | 8 (3) | 26 (6) | 1 (1) |
| Neurologic | 38 (13) | 49 (12) | 4 (3) |
| Gastrointestinal | 36 (12) | 38 (9) | 1 (1) |
| None | 77 (27) | 114 (27) | 70 (51) |
| ICU admission | 46 (16) | 136 (32) | 86 (62) |
| Ventilator | 11 (4) | 46 (11) | 22 (16) |
| ECMO | 1 (0.4) | 4 (1) | 3 (2) |
| CVC | 47 (16) | 74 (17) | 53 (38) |
| COVID-19–directed treatment | 0 | 105 (25) | 39 (28) |
| MIS-C–directed treatment | 1 (0.3) | 6 (1) | 130 (94) |
| Maximum D-dimer | |||
| Not done | 214 (74) | 197 (46) | 5 (4) |
| Normal range | 14 (5) | 36 (8) | 1 (1) |
| 1-5× ULN | 34 (12) | 131 (31) | 32 (23) |
| >5× ULN | 27 (9) | 62 (15) | 100 (72) |
| Minimum platelet count, ×103/μL | |||
| Median | 259 | 208 | 148 |
| IQR | 199-320 | 140-273 | 103-204 |
| Maximum fibrinogen, mg/dL | |||
| Median | 421 | 463 | 551 |
| IQR | 282-583 | 325-583 | 462-657 |
| Maximum PT | |||
| Not done | 183 (63) | 204 (48) | 7 (5) |
| Normal range | 55 (19) | 121 (28) | 38 (27) |
| 1-1.5× ULN | 48 (17) | 90 (21) | 86 (62) |
| >1.5× ULN | 3 (1) | 11 (3) | 7 (5) |
| Thromboprophylaxis | 31 (11) | 128 (30) | 80 (58) |
| Admission with TEs | 2 (0.7) | 9 (2) | 9 (7) |
| DVT | 2 | 4 | 7 |
| PE | 0 | 3 | 0 |
| Stroke | 0 | 0 | 1 |
| Intracardiac | 0 | 2 | 1 |
| Cerebral sinovenous thrombosis | 0 | 1 | 0 |
| Major bleeding | 4 (1) | 7 (2) | 2 (1) |
| Death during hospitalization (or <30 d) | 2 (0.7) | 11 (2.6) | 2 (1.4) |
| . | Asymptomatic SARS-CoV-2 (n = 289) . | COVID-19 (n = 426) . | MIS-C/ MIS-C like (n = 138) . |
|---|---|---|---|
| Age, y | |||
| Median | 10 | 10 | 10 |
| IQR | 3-15 | 1-16 | 6-14 |
| Male sex | 144 (50) | 226 (53) | 75 (54) |
| Ethnicity | |||
| Hispanic | 125 (43) | 228 (54) | 57 (41) |
| Non-Hispanic | 139 (48) | 167 (39) | 69 (50) |
| Unknown/other | 25 (9) | 31 (7) | 12 (9) |
| Race | |||
| White | 151 (52) | 234 (55) | 77 (56) |
| African American | 74 (26) | 89 (21) | 39 (28) |
| Asian | 2 (1) | 6 (1) | 4 (3) |
| Other/unknown | 62 (21) | 97 (23) | 18 (13) |
| African American race and/or Hispanic ethnicity | 198 (69) | 315 (74) | 96 (70) |
| Length of stay, d | |||
| Median | 3 | 3 | 6 |
| IQR | 1-7 | 2-7 | 4-10 |
| Comorbidity | |||
| Respiratory | 22 (8) | 90 (21) | 16 (12) |
| Cardiac | 13 (5) | 38 (9) | 5 (4) |
| Cancer | 25 (9) | 39 (9) | 5 (4) |
| Obesity | 61 (21) | 114 (27) | 45 (33) |
| Diabetes | 17 (6) | 15 (4) | 0 |
| Immunodeficiency | 10 (3) | 18 (4) | 1 (1) |
| Sickle cell disease | 8 (3) | 26 (6) | 1 (1) |
| Neurologic | 38 (13) | 49 (12) | 4 (3) |
| Gastrointestinal | 36 (12) | 38 (9) | 1 (1) |
| None | 77 (27) | 114 (27) | 70 (51) |
| ICU admission | 46 (16) | 136 (32) | 86 (62) |
| Ventilator | 11 (4) | 46 (11) | 22 (16) |
| ECMO | 1 (0.4) | 4 (1) | 3 (2) |
| CVC | 47 (16) | 74 (17) | 53 (38) |
| COVID-19–directed treatment | 0 | 105 (25) | 39 (28) |
| MIS-C–directed treatment | 1 (0.3) | 6 (1) | 130 (94) |
| Maximum D-dimer | |||
| Not done | 214 (74) | 197 (46) | 5 (4) |
| Normal range | 14 (5) | 36 (8) | 1 (1) |
| 1-5× ULN | 34 (12) | 131 (31) | 32 (23) |
| >5× ULN | 27 (9) | 62 (15) | 100 (72) |
| Minimum platelet count, ×103/μL | |||
| Median | 259 | 208 | 148 |
| IQR | 199-320 | 140-273 | 103-204 |
| Maximum fibrinogen, mg/dL | |||
| Median | 421 | 463 | 551 |
| IQR | 282-583 | 325-583 | 462-657 |
| Maximum PT | |||
| Not done | 183 (63) | 204 (48) | 7 (5) |
| Normal range | 55 (19) | 121 (28) | 38 (27) |
| 1-1.5× ULN | 48 (17) | 90 (21) | 86 (62) |
| >1.5× ULN | 3 (1) | 11 (3) | 7 (5) |
| Thromboprophylaxis | 31 (11) | 128 (30) | 80 (58) |
| Admission with TEs | 2 (0.7) | 9 (2) | 9 (7) |
| DVT | 2 | 4 | 7 |
| PE | 0 | 3 | 0 |
| Stroke | 0 | 0 | 1 |
| Intracardiac | 0 | 2 | 1 |
| Cerebral sinovenous thrombosis | 0 | 1 | 0 |
| Major bleeding | 4 (1) | 7 (2) | 2 (1) |
| Death during hospitalization (or <30 d) | 2 (0.7) | 11 (2.6) | 2 (1.4) |
Data presented as n (%).
CVC, central venous catheter; DVT, deep vein thrombosis; ECMO, extracorporeal membrane oxygenation; IQR, interquartile range; PE, pulmonary embolism; ULN, upper limit of normal.